Agennix hires Jill Porter as senior vice-president
This article was originally published in Scrip
Biopharmaceutical company Agennix has appointed Dr Jill Porter senior vice-president of pharmaceutical development, reporting to Dr Rajesh Malik, the company's chief medical officer. Dr Porter has held senior executive positions with responsibility for manufacturing and process development at Taligen Therapeutics, Altus Pharmaceuticals and, most recently, Alexion Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.